Pharmacodynamics of dalbavancin studied in an in vitro pharmacokinetic system

J Antimicrob Chemother. 2006 Oct;58(4):802-5. doi: 10.1093/jac/dkl311. Epub 2006 Aug 5.

Abstract

Objectives: The antibacterial effect of dalbavancin was studied against Staphylococcus aureus using stepwise declining concentrations designed to model a range of free drug concentrations observed in human serum.

Methods: Initial concentrations ranged from 0.6 to 21 mg/L and experiments were conducted over 240 h. Three vancomycin-susceptible and one vancomycin-intermediate strain of S. aureus were used.

Results and conclusions: Dalbavancin showed non-concentration-dependent killing against the three vancomycin-susceptible strains in the range 3-21 mg/L and the vancomycin-intermediate strain at 15 and 21 mg/L. AUC/MIC could be related to antibacterial effect. The AUC/MIC for a bacteriostatic effect was 36 at 24 h, 55 at 120 h and 100 at 240 h. A larger AUC/MIC was required to produce a 2 log reduction in counts, being 214 at 24 h, 195 at 120 h and 331 at 240 h.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacokinetics*
  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Area Under Curve
  • Dose-Response Relationship, Drug
  • Drug Resistance, Bacterial
  • Humans
  • Microbial Sensitivity Tests
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / growth & development
  • Teicoplanin / analogs & derivatives*
  • Teicoplanin / pharmacokinetics
  • Teicoplanin / pharmacology
  • Teicoplanin / therapeutic use
  • Vancomycin / pharmacology

Substances

  • Anti-Bacterial Agents
  • Teicoplanin
  • Vancomycin
  • dalbavancin